Northern Data AG: Northern Data Appoints Jens-Philipp Briemle as Head of Investor Relations
FRANKFURT AM MAIN, GERMANY / ACCESSWIRE / March 10, 2021 / Northern Data AG (XETRA:NB2, ISIN: DE000A0SMU87) has appointed Jens-Philipp Briemle as Head of Investor Relations to further strengthen its Investor Relations activities.
Heading the Company s strategic communications to enhance Northern Data AG s global positioning in the capital markets, Jens-Philipp Briemle will report directly to CEO Aroosh Thillainathan.
Jens-Philipp Briemle has a deep background in Investor Relations. He joins Northern Data from MDAX-listed Gerresheimer AG, a leading international provider of high-quality primary packaging where he was heading the IR department. Prior to that, he worked for SDAX-company Schaeffler AG, one of the leading automotive suppliers, and held various management positions at DAX-listed RWE AG, one of the world s largest companies for renewable energies. Jens-Philipp Briemle started his
Molecular Thyroid Research Laboratory, Department of Medicine I, Johannes Gutenberg University (JGU) Medical Center, Mainz, Germany
Type 1 diabetes (T1D) and autoimmune thyroid disease (AITD) are the most frequent chronic autoimmune diseases worldwide. Several autoimmune endocrine and non-endocrine disorders tend to occur together. T1D and AITD often cluster in individuals and families, seen in the formation of autoimmune polyendocrinopathy (AP). The close relationship between these two diseases is largely explained by sharing a common genetic background. The HLA antigens DQ2 (
DQA1 0501-DQB1 0201) and DQ8 (
DQA1 0301-DQB1 0302), tightly linked with DR3 and DR4, are the major common genetic predisposition. Moreover, functional single nucleotide polymorphisms (or rare variants) of various genes, such as the
Five Princeton faculty members named 2021 Sloan Research Fellows princeton.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from princeton.edu Daily Mail and Mail on Sunday newspapers.
DGAP-News: Secarna Pharmaceuticals GmbH & Co. KG / Key word(s): Personnel
Secarna Pharmaceuticals appoints Alexander Gebauer, MD, PhD as CEO and Managing Director
04.02.2021 / 14:00
Secarna Pharmaceuticals appoints Alexander Gebauer, MD, PhD as CEO and Managing Director
Munich/Martinsried, Germany, February 04, 2021 - Secarna Pharmaceuticals GmbH & Co. KG ( Secarna ), a biopharmaceutical company focusing on the discovery and development of next generation antisense oligonucleotide (ASO) therapies to address challenging or previously undruggable targets via its LNAplus
TM platform, announced today that the Company has appointed Alexander Gebauer, MD, PhD as CEO and Managing Director. Dr. Gebauer brings more than 25 years of experience in the pharmaceutical and biotechnology industry in leadership roles in North America, Europe and India. His focus has been on R&D, from early discovery up to launch and life cycle management, as well as business development and designing and impl
Angela Merkel is under intense pressure over Germany s slow vaccine rollout (Image: GETTY)
Mr Erb suggested the German government should seize all vaccines made in Germany to avoid legal responsibility.
He commented: “The federal government would have the de facto possibility of avoiding these additional deaths by securing the vaccine made in Germany for Germany and Europe by banning exports to third countries.”
However seizing vaccines, including those ordered by developing countries, would almost certainly spark international outrage.
Germany has also announced the AstraZeneca vaccine will only be given to those aged less than 65.
Britain has vaccinated more people than any other country in Europe (Image: EXPRESS)